Deflazacort regulatory update

Marathon submitted an NDA to FDA for deflazacort to treat Duchenne muscular dystrophy (DMD). Deflazacort has Fast Track, Orphan Drug and rare pediatric disease designation for DMD in the U.S. The prod...